Wolfe Research Downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) to Hold

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by analysts at Wolfe Research from an “outperform” rating to a “hold” rating in a report released on Tuesday, MarketBeat Ratings reports.

Several other equities analysts have also issued reports on CNTA. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Truist Financial upped their price objective on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Oppenheimer raised their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Finally, Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Centessa Pharmaceuticals Stock Up 0.4%

Centessa Pharmaceuticals stock opened at $39.86 on Tuesday. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $40.26. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The firm’s 50-day simple moving average is $26.62 and its 200 day simple moving average is $25.35. The stock has a market cap of $5.82 billion, a PE ratio of -21.78 and a beta of 1.25.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, April 6th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.10). Research analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider directly owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the completion of the sale, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals in the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Centessa Pharmaceuticals during the fourth quarter valued at about $36,000. T. Rowe Price Investment Management Inc. boosted its position in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after purchasing an additional 1,516 shares during the period. Wells Fargo & Company MN increased its stake in shares of Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after purchasing an additional 1,008 shares in the last quarter. Finally, Knott David M Jr purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $100,000. Institutional investors own 82.01% of the company’s stock.

Key Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to acquire Centessa in a deal worth up to $7.8 billion (initial $38.00/share cash plus contingent value rights), which creates a takeover premium and is the primary driver of the stock’s upward move. Eli Lilly to buy Centessa Pharma
• Positive Sentiment: Leerink Partners reaffirmed a “market perform” rating and raised its price target to $40.00, a small upward revision that supports the view the deal price is appropriate. Leerink raises price target
• Neutral Sentiment: Unusual options activity: earlier spikes in call buying and, more recently, a large surge in put purchases (10,659 puts) signal mixed positioning—some traders betting on deal completion/arb, others hedging or speculating on downside. (No single article link)
• Negative Sentiment: Multiple brokerages downgraded CNTA (Needham, Wolfe Research, Stephens), citing valuation or deal-related uncertainty — analyst downgrades can weigh on momentum despite the takeover premium. Needham downgrades
• Negative Sentiment: Several law firms and shareholder groups have announced investigations into whether the sale process and price are fair (Monteverde, Kahn Swick & Foti, Ademi, Halper Sadeh). Potential litigation or challenges to the transaction could delay closing or pressure the spread between market price and deal consideration. Shareholder investigation announced
• Negative Sentiment: Recent quarterly results missed EPS estimates (reported ($0.48) vs. consensus ($0.38)), underscoring ongoing clinical and execution risks outside the transaction context. Centessa earnings miss

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.